RSS

Concert Pharmaceuticals

Concert Pharmaceuticals has achieved a $2 million (£1.3m) milestone under its development and license agreement with Avanir Pharmaceuticals for the phase three initiation of AVP-786 for agitation in patients with Alzheimer’s more

News

Concert Pharmaceuticals has initiated a phase one multiple ascending dose clinical trial with CTP-656 for cystic fibrosis more

News

A £5.2 million ($8 million) milestone has been reached by Concert Pharmaceuticals and Celgene Corporation for the completion of a phase one clinical evaluation of CTP-730 more

News

The milestone is a result of Avanir initiating dosing in a Phase II clinical trial with AVP-786 for the adjunctive treatment of major depressive disorder. more